metaPreg - Infliximab during pregnancy

Infliximab

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	3.30 [1.43, 7.61]	0%	3 studies	28	161	not evaluable	ROB	6.05 [2.21; .]
Major congenital malformations	3.11 [1.32, 7.31]	0%	2 studies	28	158	not evaluable	ROB	5.68 [1.98; .]
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	-	-	0 study					-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal infections	4.37 [1.30, 14.71]	-	1 study	52	37	not evaluable	ROB	8.21 [1.92; .]
Neonatal disorders (as a whole)	-	-	0 study					-
Neonatal medical care	-	-	0 study					-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	-	-	0 study					-
Late intrauterine deaths (> 22 weeks)	-	-	0 study					-
Therapeutic terminations of pregnancy	-	-	0 study					-
2 non statistically significant endpoints reported in only one study